Humana (HUM) Expected to Announce Earnings on Wednesday

Humana (NYSE:HUM) will likely be announcing its Q1 2025 earnings results before the market opens on Wednesday, April 30th. Analysts expect Humana to post earnings of $9.95 per share and revenue of $32.00 billion for the quarter. Humana has set its FY 2025 guidance at 16.250-16.250 EPS.

Humana (NYSE:HUM) last announced its quarterly earnings data on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.26) by $0.10. Humana had a net margin of 1.02% and a return on equity of 11.70%. On average, analysts expect Humana to post $16 EPS for the current fiscal year and $13 EPS for the next fiscal year.

Humana Stock Performance

Humana stock opened at $258.87 on Wednesday. The stock’s 50-day moving average is $265.74 and its 200-day moving average is $270.19. The company has a market cap of $31.24 billion, a price-to-earnings ratio of 26.02, a price-to-earnings-growth ratio of 2.05 and a beta of 0.62. Humana has a 12 month low of $213.31 and a 12 month high of $406.46. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.76 and a quick ratio of 1.76.

Humana Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, July 25th. Stockholders of record on Friday, June 27th will be given a $0.885 dividend. This represents a $3.54 annualized dividend and a dividend yield of 1.37%. The ex-dividend date of this dividend is Friday, June 27th. Humana’s payout ratio is currently 35.58%.

Hedge Funds Weigh In On Humana

An institutional investor recently bought a new position in Humana stock. Revolve Wealth Partners LLC acquired a new stake in shares of Humana Inc. (NYSE:HUM) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 798 shares of the insurance provider’s stock, valued at approximately $202,000. Institutional investors own 92.38% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on HUM shares. Piper Sandler upped their target price on Humana from $270.00 to $288.00 and gave the stock a “neutral” rating in a research report on Wednesday, January 15th. Truist Financial raised their price objective on shares of Humana from $290.00 to $325.00 and gave the stock a “hold” rating in a report on Friday, April 11th. Morgan Stanley lowered their price target on Humana from $301.00 to $285.00 and set an “equal weight” rating for the company in a report on Wednesday, February 12th. Robert W. Baird lifted their price objective on shares of Humana from $270.00 to $300.00 and gave the stock a “neutral” rating in a report on Tuesday, April 15th. Finally, StockNews.com upgraded shares of Humana from a “hold” rating to a “buy” rating in a research note on Monday, April 7th. Seventeen analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat.com, Humana presently has a consensus rating of “Hold” and an average target price of $284.90.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.